Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mannitol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Galactitol SCHEMBL5578625 | 1.00 | LMNA (0.79) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL28035901 | 1.00 | LMNA (0.79) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL2489294 | 1.00 | LMNA (0.79) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL31107070 | 1.00 | LMNA (0.79) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL1079506 | 1.00 | LMNA (0.79) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Perseitol SCHEMBL16700974 | 0.97 | TDP1 (0.80) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Galactitol SCHEMBL9686277 | 0.97 | LMNA (0.73) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL28067213 | 0.94 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylitol SCHEMBL190756 | 0.93 | LMNA (0.67) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Ribitol SCHEMBL4316278 | 0.93 | LMNA (0.67) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10130580-B2 | Taste-masked pharmaceutical compositions | ADARE PHARMACEUTICALS, INC. (US) | 2018-11-20 | — | — | US | claimed |
| US-20180235877-A1 | TASTE-MASKED PHARMACEUTICAL COMPOSITIONS | TEAL MIDCO HOLDINGS, L.P. | 2018-08-23 | — | — | US | claimed |
| US-20160168259-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING sc(Fv)2 | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-06-16 | — | — | US | claimed |
| CN-105534949-A | Duloxetine hydrochloride enteric mini-pill preparation | BEIJING XIUZHENG INNOVATIVE DRUG RES INST CO LTD | 2016-05-04 | — | — | CN | claimed |
| US-8093270-B2 | Solid pharmaceutical composition comprising (R)-(−)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | claimed |
| EP-2073791-B1 | CAPECITABINE PEDIATRIC TABLETS | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | claimed |
| EP-1044015-B1 | FORMULATIONS FOR AMYLIN AGONIST PEPTIDES WITH INSULIN | AMYLIN PHARMACEUTICALS INC (US) | 2008-10-08 | — | — | EP | claimed |
| CN-101262853-A | Stable pharmaceutical composition comprising linezolid form IV | TEVA PHARMA (IL) | 2008-09-10 | — | — | CN | claimed |
| EP-0858328-B1 | STABLE COMPOSITIONS CONTAINING N-PROPARGYL-1-AMINOINDAN | TEVA PHARMA (IL) | 2007-05-23 | — | — | EP | claimed |
| EP-0783295-A1 | METHOD OF PRODUCING A LYOPHILIZED LIPOSOME PRODUCT | THE LIPOSOME COMPANY, INC. (US) | 1997-07-16 | — | — | EP | claimed |
| WO-1996009037-A1 | METHOD OF PRODUCING A LYOPHILIZED LIPOSOME PRODUCT | THE LIPOSOME COMPANY, INC. (US) | 1996-03-28 | — | — | WO | claimed |
| EP-0307087-B1 | Fluorocarbon emulsions for in vivo use | ALLIANCE PHARMA (US) | 1994-06-08 | — | — | EP | claimed |
| EP-0544097-A1 | Semi-solid mixtures of oligomers and/or polymers based on lactic acid, process for their preparation and their use as resorbable implants | BOEHRINGER INGELHEIM KG (DE) | 1993-06-02 | — | — | EP | claimed |
| EP-4362989-A2 | A NOVEL KIT FOR RADIOPHARMACEUTICAL PREPARATION OF A RADIOMETAL LABELED CHELATE-FUNCTIONALIZED TARGETING CONJUGATE | Life Molecular Imaging Limited (GB) | 2024-05-08 | — | — | EP | disclosed |
| EP-4344397-A1 | ADDITIVE SOLUTION FOR ERYTHROCYTE CONCENTRATES | Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg und Bremen g.G.m.b.H. (DE) | 2024-04-03 | — | — | EP | disclosed |
| EP-4329505-A1 | REDUCED-SUGAR SWEETENER COMPOSITION AND PROCESS FOR PREPARING SAME | Südzucker AG (DE) | 2024-03-06 | — | — | EP | disclosed |
| EP-0155848-A2 | Improved method for fixing acetaldehyde | GENERAL FOODS CORPORATION (US) | 1985-09-25 | — | — | EP | disclosed |
| US-4471114-A | ALUMINOSILICATES CONTAINING OXIDES OF BARIUM, STRONTIUM, SODIUM OR CALCIUM | UNION CARBIDE CORPORATION (US) | 1984-09-11 | — | — | US | disclosed |
| EP-0115631-A1 | Separation of mannose by selective adsorption on zeolitic molecular sieves | UNION CARBIDE CORPORATION (US) | 1984-08-15 | — | — | EP | disclosed |
| US-4327084-A | Aqueous solution for intravenous administration | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1982-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168259-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING sc(Fv)2 | IL2, CDR2, PDCD6 | LMNA 3854/4885L3MBTL1 3478/4885TDP1 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.